OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics

#3009

Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.

Aim(s): The OPERA study aimed to evaluate, in current practice, the information received and perceived by the pts and QoL, as well as to assess their evolutions between the initiation of lanreotide (LAN) and 6 months (mths) after initiation in a routine clinical care for pts with gastroenteropancreatic (GEP) NETs.

Materials and methods: Pts with histologically confirmed G1/G2 GEP NETs in whom the decision to initiate LAN 120 mg/28 days had already been taken were enrolled. Overall, 115 pts were recruited. Clinical parameters were collected, and pts completed self-administered questionnaires before treatment initiation, and after 3 and 6 mths of LAN to assess perception of physician-provided information (EORTC-QLQINFO25) and QoL (EORTC-QLQ C30, not shown).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,

Keywords: Patients’ perception of information, Quality of Life, Lanreotide,